Treatment of osteoporosis: Combination therapies

International Journal of Fertility and Women's Medicine

Volumn 48, Issue 3, 2003, Pages 127-131

  Simon, James A ^a,b,c   Mack, Carol J ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health Research Center   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonates; Combination therapy; Estrogen therapy; Osteoporosis; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; MICRONIZED PROGESTERONE; NORETHISTERONE ACETATE; PARATHYROID HORMONE; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ALENDRONATE; ANDROGENS; DIPHOSPHONATES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PROGESTINS; RALOXIFENE;

EID: 0038796585     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Speroff L, Rowan J, Symons J, et al: The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 276(17):1397-1403, 1996.
2. Christiansen C, Riis BJ, Nilas L, et al: Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 2 (8459):800-801, 1985.
3. Watts NB, Notelovitz M, Timmons MC, et al: Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid/lipoprotein profiles in surgical menopause. Obstet Gynecol 85(4):537-539, 1995.
4. Raisz LG, Wiita B, Artis A, et al: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81(1):37-43, 1996.
5. Lindsay R, Cosman F, Lobo RA, et al: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized controlled clinical trial. J Clin Endocrinol Metab 84(9):3076-3081, 1999.
6. Bone HG, Greenspan SL, McKeever C, et al: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85(2):720-726, 2000.
7. Greenspan SL, Emkey RD, Bone HG, et al: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875-883, 2002.
8. Harris ST, Eriksen EF, Davidson M, et al: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86(5):1890-1897, 2001.
9. Johnell O, Scheele WH, Lu Y, et al: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(3):985-992, 2002.
10. Dempster DW, Cosman F, Parisien M, et al: Anabolic actions of parathyroid hormone on bone. Endocrinol Rev 14(6):690-709, 1993.
11. Rittmaster RS, Bolognese M, Ettinger MP, et al: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85(6):2129-2134, 2000.
12. Watts NB: Efficacy of teriparatide and alendronate on nonvertebral fractures. J Clin Endocrinol Metab 88(3):1402-1403, 2003.